For instance, resistance in hepatocellular carcinoma involves the p-MYH9/USP22 axis stabilizing HIF-1alpha, promoting stemness and lenvatinib resistance, while in pancreatic cancer, targeting MXD1 overcomes trametinib resistance [31]. Here, MYH9 is linked to familial pancreatic carcinoma.